Harvard Bioscience Inc HBIO
Analyst Ratings
- Consensus
- Hold — 0 Buy · 1 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $7.50 (+7.6% upside)
Key Stats
- Today's Range
- $6.45 – $7.23
- 50-Day Range
- $5.77 – $7.23
- 52-Week Range
- $3.75 – $9.40
- Volume
- 51K shs
- Average Volume
- 16K shs
- Market Cap
- $29.59 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.99
- Price / Sales
- 0.34
Short Interest
- Short Interest
- 11.71%
- Days to Cover
- 8.29
Financials (TTM)
- Revenue
- $87.81 million
- Net Income
- $-10,412,000
- Net Margin
- -11.86%
- Return on Equity
- -140.36%
- Debt-to-Equity
- 4.94
About Harvard Bioscience Inc
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Related Stocks
Compare head-to-head: HBIO vs WAT·HBIO vs BIO·HBIO vs BRKR·HBIO vs TXG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.